We have observed
4 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after June 18, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
MATERIALS AND METHODS FOR DETERMINING SENSITIVITY POTENTIAL OF COMPOUNDS
FUSION PROTEINS FOR TREATING METABOLIC DISORDERS
Casein kinase 1delta (CK1delta) inhibitors